Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

PHASE3CompletedINTERVENTIONAL
Enrollment

2,336

Participants

Timeline

Start Date

April 28, 2008

Primary Completion Date

March 24, 2009

Study Completion Date

March 24, 2009

Conditions
Urinary Bladder, Overactive
Interventions
DRUG

Mirabegron

Tablets

DRUG

Tolterodine

Capsules

DRUG

Placebo to Mirabegron

Matching mirabegron placebo tablets.

DRUG

Placebo to Tolterodine

Matching tolterodine placebo capsules.

Trial Locations (218)

101

Reykjavik

1047

Budapest

1070

Brussels

1076

Budapest

1090

Brussels

1204

Budapest

2020

Antwerp

2030

Antwerp

2317

Hamar

2600

Glostrup Municipality

2650

Edegem

2700

Amadora

2800

Tatabánya

3000

Leuven

3016

Drammen

3103

Tønsberg

3300

Eger

3800

Sint-Truiden

4000

Liège

4020

Linz

4043

Debrecen

4400

Nyíregyháza

5021

Bergen

6000

Lucerne

6020

Innsbruck

6725

Szeged

7100

Szekszárd

8000

Székesfehérvár

8036

Graz

8200

Aarhus

Veszprém

8304

Mataró

8500

Kortrijk

8501

Frauenfeld

8900

Leper

9000

Ghent

9100

Aalborg

11883

Stockholm

12540

Villarreal de Huerva

12851

Prague

13274

Marseille

13285

Marseille

13347

Berlin

14056

Prague

14186

Stockholm

16128

Genoa

16151

Oranienburg

16761

Henningsdorf

17176

Stockholm

18081

Prague

18288

Stockholm

19230

Hagenow

20013

Magenta

20100

Turku

20142

Milan

20153

Milan

20253

Hamburg

21100

Varese

22328

Bucharest

24047

Treviglio

25187

Helsingborg

25436

Uetersen

27601

Mělník

27777

Ganderkesee

28016

Madrid

28046

Madrid

28905

Getafe

28942

Fuenlabrada

30029

Nîmes

30599

Pilsen

31059

Toulouse

33076

Bordeaux

33521

Tampere

40001

Ústí nad Labem

41013

Seville

41100

Modena

41108

Štětí

42055

Saint-Priest-en-Jarez

45035

Nantes

45067

Orléans

45071

Toledo

46010

Valencia

47051

Duisburg

48013

Bilbao

50139

Florence

50182

Borås

54130

Skövde

54290

Trier

56068

Koblenz

56130

Bad Ems

59129

Florence

60200

Brno

64100

Teramo

65933

Frankfurt

67000

Strasbourg

68024

Colmar

68070

Mulhouse

70124

Bari

70185

Örebro

70853

Ostrava-Poruba

75020

Paris

75185

Uppsala

75571

Paris

76031

Rouen

77200

Olomouc

80131

Naples

81925

Muenchen-Bogenhausen

86551

Aichach

88100

Catanzaro

90185

Umeå

90220

Oulu

90982

Skalica

91101

Trenčín

101000

Moscow

105425

Moscow

111020

Moscow

111123

Moscow

115516

Moscow

117049

Moscow

117815

Moscow

119435

Moscow

123836

Moscow

125206

Moscow

197089

Saint Petersburg

198013

Saint Petersburg

220036

Minsk

220119

Minsk

223041

Minsk

Unknown

Auchenflower

Clayton

Kogarah

Randwick

Woolloongabba

Pleven

Sofia

Varna

Roskilde

Athens

Nikaias-Piraeus

Pátrai

Thessaloniki

Pápa

Sopron

Cork

Dublin

Mullingar

Tralee

Liepāja

Riga

Kaunas

Vilnius

Apeldoorn

Bucharest

Lasi

Oradea

Timișoara

Bloemfontein

Hatfield

Lyttelton

Paarl

Pietermaritzburg

Madrid

00029

Helsinki

02625

Bautzen

06295

Eisleben Lutherstadt

06132

Halle

06333

Hettstedt

04105

Leipzig

01844

Neustadt in Sachsen

01445

Radebeul

06526

Sangerhausen

04100

Latina

06122

Perugia

1105 AZ

Amsterdam

7334 DZ

Apeldoorn

5623 EJ

Eindhoven

7511 JX

Enschede

2334 CK

Leiden

6229 HX

Maastricht

6532 SZ

Nijmegen

8600 BA

Sneek

5022 GC

Tilburg

7101 BN

Winterswijk

0257

Oslo

15-278

Bialystok

41-500

Chorzów

93-338

Lodz

93-513

Lodz

20-954

Lublin

00-846

Warsaw

02-005

Warsaw

02-507

Warsaw

50-556

Wroclaw

4099-005

Porto

2304-909

Tomar

4900-858

Viana do Castelo

03659

Martin

05801

Poprad

01207

Žilina

08020

Barcelona

08950

Esplugues de Llobregat-Barcelo

09200

Miranda de Ebro

07014

Palma de Mallorca

01023

Kiev

04053

Kiev

B15 2TG

Birmingham

PR7 7NA

Chorley

CR7 7YE

Croydon

L22 OLG

Liverpool

SE5 9RS

London

W2 2YP

London

M15 6SX

Manchester

NE7 7DN

Newcastle upon Tyne

HA6 2RN

Northwood

RG1 5AN

Reading

RG2 7AG

Reading

S10 2JF

Sheffield

SA6 6NL

Swansea

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY

NCT00689104 - Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder | Biotech Hunter | Biotech Hunter